CR20160022A - Compuestos de n,6-bis (aril o heteroaril) 1,3,5- triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento del cancer - Google Patents
Compuestos de n,6-bis (aril o heteroaril) 1,3,5- triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento del cancerInfo
- Publication number
- CR20160022A CR20160022A CR20160022A CR20160022A CR20160022A CR 20160022 A CR20160022 A CR 20160022A CR 20160022 A CR20160022 A CR 20160022A CR 20160022 A CR20160022 A CR 20160022A CR 20160022 A CR20160022 A CR 20160022A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- inhibitors
- cancer
- heteroaril
- aril
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Abstract
Se proporcionan compuestos de la fórmula (I), en donde: el anillo A y el anillo B son cada uno independientemente un arilo o heteroarilo monocíclico sustituido opcionalmente de 5-6 miembros. Los compuestos son inhibidores de los mutantes de la isocitrato deshidrogenasa 2(IDH2) útiles para tratar cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361845352P | 2013-07-11 | 2013-07-11 | |
PCT/US2014/046204 WO2015006592A1 (en) | 2013-07-11 | 2014-07-10 | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20160022A true CR20160022A (es) | 2016-05-17 |
Family
ID=51261261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20160022A CR20160022A (es) | 2013-07-11 | 2016-01-11 | Compuestos de n,6-bis (aril o heteroaril) 1,3,5- triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento del cancer |
Country Status (24)
Country | Link |
---|---|
US (2) | US9724350B2 (es) |
EP (1) | EP3019490B1 (es) |
JP (1) | JP6471155B2 (es) |
KR (1) | KR102302091B1 (es) |
CN (1) | CN105492435B (es) |
AU (1) | AU2014287122B9 (es) |
BR (1) | BR112016000489A8 (es) |
CA (1) | CA2917592A1 (es) |
CL (1) | CL2016000045A1 (es) |
CR (1) | CR20160022A (es) |
EA (1) | EA032070B1 (es) |
ES (1) | ES2807582T3 (es) |
IL (1) | IL243522B (es) |
MX (1) | MX2016000336A (es) |
MY (1) | MY185687A (es) |
NI (1) | NI201600007A (es) |
NZ (1) | NZ715738A (es) |
PE (1) | PE20160744A1 (es) |
PH (1) | PH12016500055B1 (es) |
SA (1) | SA516370386B1 (es) |
SG (1) | SG11201600058XA (es) |
UA (1) | UA119242C2 (es) |
WO (1) | WO2015006592A1 (es) |
ZA (1) | ZA201600210B (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
CA2917592A1 (en) * | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer |
CN105593215B (zh) | 2013-07-11 | 2019-01-15 | 安吉奥斯医药品有限公司 | 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物 |
WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
UA121021C2 (uk) | 2013-08-02 | 2020-03-25 | Аджіос Фармасьютікалз, Інк. | Терапевтично активні сполуки і способи їх застосування |
EP3200800A1 (en) | 2014-09-29 | 2017-08-09 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
CN107531675A (zh) | 2015-02-04 | 2018-01-02 | 安吉奥斯医药品有限公司 | 治疗活性化合物及其使用方法 |
CN108349933A (zh) | 2015-08-05 | 2018-07-31 | 安吉奥斯医药品有限公司 | 制备6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二醇和6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二胺的方法 |
BR112018007304A2 (pt) | 2015-10-15 | 2018-10-23 | Agios Pharmaceuticals Inc | terapia de combinação para tratamento de malignidades |
EP3362070B1 (en) * | 2015-10-15 | 2021-01-27 | Celgene Corporation | Combination of a mutant isocitrate dehydrogenase 2 inhibitor with azacitidine and its use for treating acute myelogenous leukemia |
JP6852073B2 (ja) | 2015-12-04 | 2021-03-31 | アジオス ファーマシューティカルズ, インコーポレイテッド | 悪性病変を処置する方法 |
WO2017140758A1 (en) | 2016-02-19 | 2017-08-24 | Debiopharm International S.A. | Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers |
MX2018010252A (es) | 2016-02-26 | 2019-01-31 | Celgene Corp | Inhibidores de idh2 para el tratamiento de neoplasias malignas hematologicas y tumores solidos. |
CN107382840B (zh) * | 2016-05-16 | 2020-09-01 | 四川大学 | 吡啶类化合物及其作为idh功能变异突变体抑制剂类药物的用途 |
CN107556366A (zh) * | 2016-06-30 | 2018-01-09 | 上海海和药物研究开发有限公司 | 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途 |
EP3489230B1 (en) | 2016-07-21 | 2021-12-08 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Chemical compound of isocitrate dehydrogenase inhibitor, and application thereof |
US20180042930A1 (en) | 2016-08-03 | 2018-02-15 | Celgene Corporation | Methods of treatment of malignancies |
CA3036053A1 (en) | 2016-09-07 | 2018-03-15 | Celgene Corporation | Tablet compositions |
EP3618828B1 (en) | 2017-05-05 | 2023-11-01 | Memorial Sloan Kettering Cancer Center | Methods of treatment of myeloproliferative neoplasm |
PL3644999T3 (pl) | 2017-06-30 | 2023-05-08 | Celgene Corporation | Kompozycje i sposoby zastosowania 2-(4-chlorofenylo)-n-((2-(2,6-dioksopiperydyn-3-ylo)-1-oksoizoindolin-5-ylo)metylo)-2,2-difluoroacetamidu |
CN109467538A (zh) * | 2017-09-07 | 2019-03-15 | 和记黄埔医药(上海)有限公司 | 环烯烃取代的杂芳环类化合物及其用途 |
CN110054617A (zh) * | 2018-01-19 | 2019-07-26 | 南京圣和药业股份有限公司 | 三嗪类化合物、其制备方法及用途 |
CN111662242B (zh) * | 2019-03-08 | 2023-10-24 | 中国药科大学 | 杂环类idh突变体抑制剂、其制备方法及用途 |
CN111087408B (zh) * | 2020-01-03 | 2021-04-02 | 浙江大学 | 一种大环结构的idh2突变体抑制剂及其医药用途 |
CN112250639B (zh) * | 2020-11-19 | 2022-05-24 | 浙江工业大学 | 一种杂环取代的芳胺类化合物及其制备方法和应用 |
CN112592958B (zh) * | 2020-12-07 | 2022-11-01 | 山东大学第二医院 | 利用fad依赖型d-2-羟基戊二酸脱氢酶和刃天青检测d-2-羟基戊二酸的方法 |
CN112645893A (zh) * | 2020-12-28 | 2021-04-13 | 营口昌成新材料科技有限公司 | 一种二卤代均三嗪的合成方法 |
CN115536637A (zh) * | 2022-10-24 | 2022-12-30 | 陕西中医药大学 | 一种均三嗪类衍生物及其合成方法与用途 |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2390529A (en) * | 1942-02-03 | 1945-12-11 | Ernst A H Friedheim | Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds |
BE754242A (fr) | 1970-07-15 | 1971-02-01 | Geigy Ag J R | Diamino-s-triazines et dinitro-s-triazines |
US3867383A (en) | 1971-03-29 | 1975-02-18 | Ciba Geigy Corp | Monoanthranilatoanilino-s-triazines |
JPS5011392B2 (es) * | 1971-08-07 | 1975-04-30 | ||
CH606334A5 (es) | 1974-06-21 | 1978-10-31 | Ciba Geigy Ag | |
JPS58186682A (ja) * | 1982-04-27 | 1983-10-31 | 日本化薬株式会社 | セルロ−ス又はセルロ−ス含有繊維材料の染色法 |
DE3512630A1 (de) * | 1985-04-06 | 1986-10-23 | Hoechst Ag, 6230 Frankfurt | Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern |
WO1993017009A1 (en) | 1992-02-28 | 1993-09-02 | Zenyaku Kogyo Kabushiki Kaisha | s-TRIAZINE DERIVATIVE AND REMEDY FOR ESTROGEN-DEPENDENT DISEASES CONTAINING THE SAME AS ACTIVE INGREDIENT |
WO1998021191A1 (fr) | 1995-05-16 | 1998-05-22 | Nissan Chemical Industries, Ltd. | Derives de cyanoethylmelamine et procede de production |
GB9602166D0 (en) | 1996-02-02 | 1996-04-03 | Zeneca Ltd | Aminoheterocyclic derivatives |
JPH11158073A (ja) | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | アデノシンa3拮抗剤 |
US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
UY25842A1 (es) | 1998-12-16 | 2001-04-30 | Smithkline Beecham Corp | Antagonistas de receptores de il-8 |
EP1187825A1 (en) * | 1999-06-07 | 2002-03-20 | Shire Biochem Inc. | Thiophene integrin inhibitors |
JP2005500294A (ja) | 2001-06-19 | 2005-01-06 | ブリストル−マイヤーズ スクイブ カンパニー | ホスホジエステラーゼ7に対するピリミジン阻害剤 |
DK1423371T3 (da) | 2001-08-17 | 2011-02-07 | Basf Se | Triazinderivater og anvendelse deraf som solbeskyttelse |
JP4753336B2 (ja) | 2001-09-04 | 2011-08-24 | 日本化薬株式会社 | 新規アリル化合物及びその製法 |
US7291616B2 (en) * | 2001-10-31 | 2007-11-06 | Cell Therapeutics, Inc. | Aryl triazines as LPAAT-β inhibitors and uses thereof |
US6878196B2 (en) | 2002-01-15 | 2005-04-12 | Fuji Photo Film Co., Ltd. | Ink, ink jet recording method and azo compound |
HUE029020T2 (en) * | 2002-07-18 | 2017-02-28 | Janssen Pharmaceutica Nv | Substituted triazine kinase inhibitors |
JP2004107220A (ja) | 2002-09-13 | 2004-04-08 | Mitsubishi Pharma Corp | TNF−α産生抑制剤 |
CL2003002353A1 (es) | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
AU2003293333A1 (en) | 2002-12-02 | 2004-06-23 | Arqule, Inc. | Method of treating cancers |
NZ541050A (en) | 2002-12-16 | 2010-06-25 | Genmab As | Human monoclonal antibodies against interleukin 8 (IL-8) |
EP1689722A2 (en) | 2003-10-10 | 2006-08-16 | Bayer Pharmaceuticals Corporation | 4-aminopyrimidine derivatives for treatment of hyperproliferative disorders |
WO2005060956A1 (en) | 2003-12-12 | 2005-07-07 | University Of Maryland, Baltimore | IMMUNOMODULATORY COMPOUNDS THAT TARGET AND INHIBIT THE pY+3 BINDING SITE OF TYROSENE KINASE p56 LCK SH2 DOMAIN |
RU2006122519A (ru) | 2003-12-24 | 2008-01-27 | Сайос, Инк. (Us) | Лечение злокачественных глиом ингибиторами тфр-бэта |
RU2007110731A (ru) | 2004-09-23 | 2008-10-27 | Редди Юс Терапевтикс | Новые соединения пиримидина, способ их получения и содержащие их композиции |
CA2594708A1 (en) | 2005-01-25 | 2006-08-03 | Astrazeneca Ab | Chemical compounds |
US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
TW200815426A (en) | 2006-06-28 | 2008-04-01 | Astrazeneca Ab | New pyridine analogues II 333 |
WO2008070661A1 (en) | 2006-12-04 | 2008-06-12 | Neurocrine Biosciences, Inc. | Substituted pyrimidines as adenosine receptor antagonists |
EP2425840B1 (en) | 2006-12-15 | 2015-04-08 | Abraxis BioScience, Inc. | Triazine derivatives and their therapeutical applications |
US8258295B2 (en) | 2007-04-30 | 2012-09-04 | Prometic Biosciences Inc. | Triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives |
WO2008154026A1 (en) | 2007-06-11 | 2008-12-18 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
US20090163508A1 (en) | 2007-10-10 | 2009-06-25 | Takeda Pharmaceutical Company Limited | Amide compound |
AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
JP5277685B2 (ja) | 2008-03-26 | 2013-08-28 | 富士ゼロックス株式会社 | 電子写真感光体、画像形成装置、プロセスカートリッジ及び画像形成方法 |
GB0805477D0 (en) * | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
CN101575408B (zh) | 2008-05-09 | 2013-10-30 | Mca技术有限公司 | 用作阻燃剂和光稳定剂的聚三嗪基化合物 |
WO2010028179A1 (en) | 2008-09-03 | 2010-03-11 | Dr. Reddy's Laboratories Ltd. | Heterocyclic compounds as gata modulators |
JP2010079130A (ja) | 2008-09-29 | 2010-04-08 | Fuji Xerox Co Ltd | 電子写真感光体、プロセスカートリッジ、及び画像形成装置 |
JP2010181540A (ja) | 2009-02-04 | 2010-08-19 | Fuji Xerox Co Ltd | 電子写真感光体、プロセスカートリッジ、及び画像形成装置 |
ES2453474T3 (es) | 2009-02-06 | 2014-04-07 | Nippon Shinyaku Co., Ltd. | Derivados de aminopirazina y medicamento correspondiente |
ES2740424T3 (es) | 2009-03-13 | 2020-02-05 | Agios Pharmaceuticals Inc | Métodos y composiciones para trastornos relacionados con la proliferación celular |
AU2010259002B2 (en) | 2009-06-08 | 2014-03-20 | Nantbio, Inc. | Triazine derivatives and their therapeutical applications |
WO2010144404A1 (en) | 2009-06-09 | 2010-12-16 | Abraxis Bioscience, Llc | Pyridil-triazine inhibitors of hedgehog signaling |
WO2010144522A1 (en) * | 2009-06-09 | 2010-12-16 | Abraxis Bioscience, Llc | Ureidophenyl substituted triazine derivatives and their therapeutical applications |
US20120101587A1 (en) | 2009-07-10 | 2012-04-26 | Milux Holding Sa | Knee joint device and method |
JP5473851B2 (ja) | 2009-09-30 | 2014-04-16 | 富士フイルム株式会社 | 高分子フィルム、位相差フィルム、偏光板及び液晶表示装置 |
ES2812537T3 (es) | 2009-10-21 | 2021-03-17 | Agios Pharmaceuticals Inc | Métodos y composiciones para trastornos relacionados con la proliferación celular |
EP3064595B1 (en) | 2009-10-21 | 2019-02-27 | Agios Pharmaceuticals, Inc. | Methods for cell-proliferation-related disorders |
EP2509600B1 (en) | 2009-12-09 | 2017-08-02 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation |
EP2553116A4 (en) | 2010-04-01 | 2013-10-23 | Agios Pharmaceuticals Inc | METHOD FOR IDENTIFYING A CANDIDATE COMPOUND |
ES2704862T3 (es) | 2010-07-16 | 2019-03-20 | Agios Pharmaceuticals Inc | Composiciones terapéuticamente activas y su método de uso |
US9351972B2 (en) | 2010-11-29 | 2016-05-31 | Galleon Pharmaceuticals, Inc. | Compounds as respiratory stimulants for treatment of breathing control disorders or diseases |
EP2691391A4 (en) | 2011-03-29 | 2014-09-10 | Broad Inst Inc | COMPOUNDS AND METHODS FOR THE TREATMENT OF DISEASES RELATED TO ISOCITRATE DEHYDROGENASE |
CN102250065B (zh) * | 2011-05-20 | 2015-05-13 | 浙江海正药业股份有限公司 | 取代的三嗪苯脲衍生物及其用途 |
TW201636330A (zh) | 2011-05-24 | 2016-10-16 | 拜耳知識產權公司 | 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺 |
CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
CN102659765B (zh) | 2011-12-31 | 2014-09-10 | 沈阳药科大学 | 嘧啶及三嗪类化合物的制备方法和应用 |
SG10201602862RA (en) * | 2012-01-06 | 2016-05-30 | Agios Pharmaceuticals Inc | Therapeutically Active Compounds And Their Methods Of Use |
JP6228130B2 (ja) | 2012-01-19 | 2017-11-08 | アジオス ファーマシューティカルズ, インコーポレイテッド | 治療活性化合物およびそれらの使用方法 |
US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
EP2824099A4 (en) * | 2012-03-09 | 2015-11-11 | Carna Biosciences Inc | NOVEL TRIAZINE DERIVATIVE |
CA2917592A1 (en) * | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer |
US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
-
2014
- 2014-07-10 CA CA2917592A patent/CA2917592A1/en not_active Abandoned
- 2014-07-10 CN CN201480047026.XA patent/CN105492435B/zh active Active
- 2014-07-10 US US14/904,032 patent/US9724350B2/en active Active
- 2014-07-10 EA EA201690204A patent/EA032070B1/ru not_active IP Right Cessation
- 2014-07-10 KR KR1020167003352A patent/KR102302091B1/ko active IP Right Grant
- 2014-07-10 EP EP14745309.6A patent/EP3019490B1/en active Active
- 2014-07-10 PE PE2016000042A patent/PE20160744A1/es unknown
- 2014-07-10 AU AU2014287122A patent/AU2014287122B9/en active Active
- 2014-07-10 MX MX2016000336A patent/MX2016000336A/es active IP Right Grant
- 2014-07-10 SG SG11201600058XA patent/SG11201600058XA/en unknown
- 2014-07-10 JP JP2016525491A patent/JP6471155B2/ja active Active
- 2014-07-10 ES ES14745309T patent/ES2807582T3/es active Active
- 2014-07-10 WO PCT/US2014/046204 patent/WO2015006592A1/en active Application Filing
- 2014-07-10 MY MYPI2016700044A patent/MY185687A/en unknown
- 2014-07-10 BR BR112016000489A patent/BR112016000489A8/pt not_active Application Discontinuation
- 2014-07-10 NZ NZ715738A patent/NZ715738A/en unknown
- 2014-10-07 UA UAA201601118A patent/UA119242C2/uk unknown
-
2016
- 2016-01-07 PH PH12016500055A patent/PH12016500055B1/en unknown
- 2016-01-07 IL IL243522A patent/IL243522B/en active IP Right Grant
- 2016-01-08 NI NI201600007A patent/NI201600007A/es unknown
- 2016-01-11 SA SA516370386A patent/SA516370386B1/ar unknown
- 2016-01-11 CR CR20160022A patent/CR20160022A/es unknown
- 2016-01-11 CL CL2016000045A patent/CL2016000045A1/es unknown
- 2016-01-11 ZA ZA2016/00210A patent/ZA201600210B/en unknown
-
2017
- 2017-06-22 US US15/630,886 patent/US10111878B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20160022A (es) | Compuestos de n,6-bis (aril o heteroaril) 1,3,5- triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento del cancer | |
CO2019008783A2 (es) | Compuestos dinucleotidos ciclicos para el tratamiento del cancer | |
EA201591612A1 (ru) | ПРИМЕНЕНИЕ ПИРАЗОЛПИРИМИДИНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ С PI3Kδ | |
EA201690713A1 (ru) | Гетероциклические соединения и их применения | |
CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
MY198613A (en) | Nitrobenzyl derivatives of anti-cancer agents | |
EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
MX2016012097A (es) | Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer. | |
EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
GEP20186933B (en) | Substituted dihydroisoquinoline compounds | |
EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
EA201591362A1 (ru) | Соединения и способы лечения бактериальных инфекций | |
EA201790327A1 (ru) | Соединения замещенного пиперидина | |
CO2017001528A2 (es) | Compuestos novedosos de pirimidina sustituidos | |
MX2018010993A (es) | Derivados de icariina e icaritina. | |
CO2017001506A2 (es) | Compuestos novedosos de pirimidina sustituidos | |
MX2018001576A (es) | Piridinas y su uso en el tratamiento del cancer. | |
EA201792287A1 (ru) | Способы лечения рака | |
MD3395821T2 (ro) | Compuși antitumorali | |
CL2016001623A1 (es) | Compuestos de benzamida y nicotinamida y métodos para usar los mismos. | |
BR112019003130A2 (pt) | agonista de ppargama para tratamento de cânceres de sangue | |
EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
EA201591709A1 (ru) | 5-бром-индирубины | |
BR112017009854A2 (pt) | composto, uso de um composto, e, método para tratamento de leucemia. | |
EA201791745A1 (ru) | Производные тетрагидропиранилбензамида |